Management of Medication-Related Osteonecrosis of the Jaw

William Bradford Williams; Felice O'Ryan

doi:10.1016/j.coms.2015.06.007

Management of Medication-Related Osteonecrosis of the Jaw

Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):517-25. doi: 10.1016/j.coms.2015.06.007.

Authors

William Bradford Williams¹, Felice O'Ryan²

Affiliations

¹ Division Maxillofacial Surgery, Oakland Medical Center, Kaiser Permanente, 3600 Broadway Kaiser, Oakland, CA 94611, USA.
² Division Maxillofacial Surgery, Oakland Medical Center, Kaiser Permanente, 3600 Broadway Kaiser, Oakland, CA 94611, USA. Electronic address: Felice.O'Ryan@kp.org.

PMID: 26515735
DOI: 10.1016/j.coms.2015.06.007

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) primarily involves patients receiving intravenous bisphosphonates for treatment of skeletal-related malignancies, oral bisphosphonates, and denosumab. There is no consensus regarding the clinical management of MRONJ. Successful treatment may be that which results in a cure, with complete mucosal coverage and elimination of disease, or that which improves the quality of life without a cure (palliation). Helping patients to understand the chronicity and potential progression of the disease is essential to a satisfactory outcome. This review aims to share our treatment approach to patients with MRONJ. Treatment can be divided into medical and surgical therapies.

Keywords: BRONJ; Bisphosphonate; Denosumab; MRONJ; Maxillofacial surgery; Oral surgery.

Publication types

Review

MeSH terms

Bisphosphonate-Associated Osteonecrosis of the Jaw / therapy*
Bone Density Conservation Agents / adverse effects*
Denosumab / adverse effects*
Diphosphonates / adverse effects*
Disease Progression
Humans

Substances

Bone Density Conservation Agents
Diphosphonates
Denosumab